It starts with a target

📍 Where we are: Part 1 of the journey — before any cell or factory, we choose what the medicine should attack.

Every biologic medicine begins long before a single cell is grown. It begins with a disease and a question: what, exactly, is going wrong inside the body, and what could we grab onto to fix it? That "something to grab onto" is called the target.

The simple version

Think of building a house. Nobody pours concrete on day one. First an architect draws a blueprint, and everyone agrees on it: how many rooms, where the door goes, what it is for. Only then do builders start. In medicine, choosing the target and writing the wish-list for the drug is that blueprint. Get the blueprint wrong, and the most beautiful house is still the wrong house.

What actually happens

A biologic is a medicine made from living cells — usually a protein (a tiny biological machine the body builds from instructions in your genes). The most common kind is a monoclonal antibody (mAb): a Y-shaped protein designed to stick to one specific thing, and one thing only. To design it, scientists first decide what it should stick to.

1. Target identification. Researchers study a disease and look for a target — usually a specific protein in the body that drives the disease. Maybe a protein that feeds a tumor so it keeps growing. Maybe a protein that turns up inflammation until a joint swells and aches. Find the protein doing the damage, and you have found something to aim at.
2. Target validation. Finding a suspect is not the same as proving guilt. Validation means showing that hitting this target actually helps — that blocking the protein slows the tumor or calms the inflammation, and does not break something the body needs. Scientists test this in cells and in animals before trusting it.
3. Writing the Target Product Profile (TPP). With a validated target, the team writes a Target Product Profile (TPP) — the official wish-list, or "spec sheet," for the future drug. It is agreed up front, and it guides every decision for years.

The TPP answers concrete questions:

• Which disease and which patients? (Children? Adults? People who tried other drugs first?)
• How is it given? Dripped slowly into a vein in a clinic (an IV infusion), or a quick shot under the skin at home (a subcutaneous injection)?
• How often, and what dose? Once a week? Once a month?
• How long must it stay good? Its shelf life, and whether it must be kept cold.

Why it matters

This is the most powerful step in the whole journey, precisely because it comes first. A clever antibody aimed at the wrong target is useless — like a perfectly built key for a lock that opens nothing. Years of work and a great deal of money can be lost chasing a target that turns out not to matter. Strong validation is how teams avoid that heartbreak.

The TPP matters for patient safety and for everything downstream. If the wish-list says "a shot patients give themselves at home," the drug must be concentrated enough to fit in a tiny volume, and stable enough to survive a fridge — and those promises shape how the cells are grown, how the protein is purified, and how it is finally bottled. Decide it now, on paper, and the rest of the factory can be built to hit it. Discover it too late, and you may have to start over.

In the real world

The TPP quietly sets the ambition for the entire manufacturing plan. A profile demanding very high doses, or huge numbers of patients, pushes a company to make a lot of protein. The standard answer today is large stainless-steel tanks run in fed-batch mode (we feed the cells in batches). A newer, more efficient answer — continuous, intensified manufacturing using perfusion — is being pioneered in the U.S. by the NIIMBL institute and its SABRE pilot facility. Both paths trace back to the same starting line: the target and the TPP agreed here.

Key terms

• Target — the specific thing in the body (usually a protein) that a drug is designed to act on.
• Target identification — finding the protein that drives a disease.
• Target validation — proving that hitting that target actually helps, with acceptable safety.
• Target Product Profile (TPP) — the agreed wish-list or spec sheet for the future drug: disease, patients, dose, how it is given, and shelf life.
• Biologic — a medicine made by living cells, usually a protein.
• Monoclonal antibody (mAb) — a Y-shaped protein engineered to stick to one specific target.
• IV infusion — a drug given slowly into a vein. Subcutaneous injection — a shot given just under the skin.